Hemostasis Today

February, 2026
February 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
232425262728  
Marios Georgakis: An Unprecedented for An Antithrombotic Therapy from OCEANIC-STROKE Trial
Feb 23, 2026, 12:02

Marios Georgakis: An Unprecedented for An Antithrombotic Therapy from OCEANIC-STROKE Trial

Marios Georgakis, Research Group Leader and Physician at LMU Munich, Visiting Scientist at Broad Institute of MIT and Harvard University, shared on LinkedIn:

”In another win for genetically validated drug targets, a small molecule factor XI inhibitor on top of antiplatelet treatment, led to significant reductions (HR: 0.74, 95%CI: 0.65–0.84) in risk of recurrent ischemic stroke among patients with a non-cardioembolic ischemic stroke or TIA in the placebo-controlled OCEANIC-STROKE trial (12,327 patients).

As predicted by Mendelian randomization analyses several years ago, the benefit against ischemic stroke was not accompanied by an increase in risk of major bleeding, intracranial bleeding, or even minor bleeding.

This is unprecedented for an antithrombotic therapy.

Also interestingly, human genetic analyses had long supported no effects on myocardial infarction or coronary artery disease risk, which also lines up with the underwhelming available trial data in patients with acute myocardial infarction.”

Find the full results.

Marios Georgakis: An Unprecedented for An Antithrombotic Therapy from OCEANIC-STROKE Trial

Stay updated with Hemostasis Today.